Camber Spine Enters Cellular Bone Graft Market

Through a private label agreement, Camber Spine will offer SCYLLA™, an allogeneic bone matrix product containing viable spine-derived cells. The product is complementary to Camber's SPIRA® and ENZA® spinal fusion technology platforms.

To support bone formation, SCYLLA contains an osteoconductive three-dimensional scaffold with cortical and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0